AFP and pneumocystosis: Overall, 6.3% of patients died during the study (three during AFP phase, three during follow-up); The causes of death included: two candidemia (1/2 with concomitant persistent E. faecium bacteremia), two GVHD, one graft failure and one Pneumocystis jirovecii pneumonia;Not assessed;45% of patients developed a-GVHD grade ≥ 2;7.4% of patients stopped ISA AFP due to treatment emergent toxicity (mainly liver);C. parapsilosis strains were sensitive to FCZ (ISA sensitivity testing was not carried out).